| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/29/2010 | US20100190800 Combinaton of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases |
| 07/29/2010 | US20100190798 Pharmaceutical composition comprising racemic aminopterin |
| 07/29/2010 | US20100190791 Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners |
| 07/29/2010 | US20100190790 Sigma receptor inhibitors |
| 07/29/2010 | US20100190788 Amide derivatives as kinase inhitors |
| 07/29/2010 | US20100190786 Indolin-2-ones and aza-indolin-2-ones |
| 07/29/2010 | US20100190785 Method for the purification of mycophenolate mofetil |
| 07/29/2010 | US20100190782 Compounds and methods of use |
| 07/29/2010 | US20100190781 Sigma receptor inhibitors |
| 07/29/2010 | US20100190780 Sigma receptor inhibitors |
| 07/29/2010 | US20100190777 Compounds and methods for kinase modulation, and indications therefor |
| 07/29/2010 | US20100190774 Inhibitors of c-met and uses thereof |
| 07/29/2010 | US20100190769 Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
| 07/29/2010 | US20100190763 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
| 07/29/2010 | US20100190762 Triazolyl phenyl benzenesulfonamides |
| 07/29/2010 | US20100190756 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS |
| 07/29/2010 | US20100190749 Benzoxazole kinase inhibitors and methods of use |
| 07/29/2010 | US20100190746 Quinazolinones as potassium channel modulators |
| 07/29/2010 | US20100190738 Use of Aalkylphophocholines in Combination with Antitumor Medication for the Treatment of Benign and Melignant Oncoses in Humans and Mammals |
| 07/29/2010 | US20100190736 Morpholinyl anthracycline derivative combined with protein kinase inhibitors |
| 07/29/2010 | US20100190725 Amino acid derivatives |
| 07/29/2010 | US20100190724 Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 07/29/2010 | US20100190722 Substance p and thyrotropin releasing hormone for therapeutic applications |
| 07/29/2010 | US20100190720 Compositions and Methods for Preventing or Treating Cancer |
| 07/29/2010 | US20100190713 Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
| 07/29/2010 | US20100190712 Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine |
| 07/29/2010 | US20100190711 Big gastrin i as a therapeutic agent |
| 07/29/2010 | US20100190702 Compositions and Methods of Treating Neoplasia |
| 07/29/2010 | US20100190694 Methods for identifying patients who will respond well to cancer treatment |
| 07/29/2010 | US20100190692 Methods for reducing gnrh-positive tumor cell proliferation |
| 07/29/2010 | US20100190688 Tetrapeptide analogs |
| 07/29/2010 | US20100190685 Prognostic factor in sarcoma, and metastasis inhibitor |
| 07/29/2010 | US20100189824 Triterpene compositions and methods for use thereof |
| 07/29/2010 | US20100189807 Use of an ozone / oxygen mixture as a primary anticancer therapy via intraperitoneal insufflation |
| 07/29/2010 | US20100189803 Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc. |
| 07/29/2010 | US20100189784 Use of Alkylphophocholine in Combination with Antitumor Medication for the Treatment of Benign and Malignant Oncoses in Humans and Mammals |
| 07/29/2010 | US20100189781 Alkoxyalkyl s-prenylthiosalicylates for treatment of cancer |
| 07/29/2010 | US20100189776 Anti-androgen peptides and uses thereof in cancer therapy |
| 07/29/2010 | US20100189775 Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma |
| 07/29/2010 | US20100189773 5-cyano-4- (pyrrolo [2,3] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| 07/29/2010 | US20100189771 Fixed ratio drug combination treatments for solid tumors |
| 07/29/2010 | US20100189770 Bioerodible patch |
| 07/29/2010 | US20100189762 Triarylmethane analogs and their use in treating cancers |
| 07/29/2010 | US20100189750 Methods of treating tumors in immune-privileged sites |
| 07/29/2010 | US20100189739 Immunogenic compositions comprising dal/dat double mutant, auxotrophic attenuated strains of Listeria and their methods of use |
| 07/29/2010 | US20100189727 Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| 07/29/2010 | US20100189726 Lpaat-beta inhibitors and uses thereof |
| 07/29/2010 | US20100189725 P53 modulator and cancer target |
| 07/29/2010 | US20100189724 Method for screening of patient to be administered with pharmaceutical agent comprising anti-cancer antibody as active ingredient |
| 07/29/2010 | US20100189723 Anti-kir antibodies, formulations, and uses thereof |
| 07/29/2010 | US20100189722 Anti cd37 antibodies |
| 07/29/2010 | US20100189720 Novel card proteins involved in cell death regulation |
| 07/29/2010 | US20100189719 using monoclonal antibody or an Fab fragment capable of binding to mouse Vascular endothelial cell growth factor (VEGF) and human VEGF; cancer, diabetes related diseases, age-induced macular degeneration |
| 07/29/2010 | US20100189716 Treatment of hodgkins lymphoma |
| 07/29/2010 | US20100189711 Tumor immunity |
| 07/29/2010 | US20100189691 E. Coli Mediated Gene Silencing of Beta-Catenin |
| 07/29/2010 | US20100189690 Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high throughput screening |
| 07/29/2010 | US20100189689 Tetrameric Cytokines with Improved Biological Activity |
| 07/29/2010 | US20100189686 Albumin Fusion Proteins |
| 07/29/2010 | US20100189683 Pulsatile Dosing of Gossypol for Treatment of Disease |
| 07/29/2010 | US20100189682 Biologically active proteins having increased In Vivo and/or In Vitro stability |
| 07/29/2010 | US20100189681 Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer |
| 07/29/2010 | US20100189680 Methods of Treating Various Cancers Using Melanoma Differentiating Associated Protein-7 |
| 07/29/2010 | US20100189657 Intramolecularly quenched fluorochrome conjugates and methods of use |
| 07/29/2010 | US20100189652 Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof |
| 07/29/2010 | US20100189651 Modified antibody compositions, methods of making and using thereof |
| 07/29/2010 | US20100189649 Monoclonal antibodies to activated erbb family members and methods of use |
| 07/29/2010 | US20100189648 Inhibitors for disrupting the interaction of ubiquitination related enzymes and uses thereof |
| 07/29/2010 | US20100189645 Metal chelators and methods of their use |
| 07/29/2010 | US20100189644 Arginase inhibitors and methods of use |
| 07/29/2010 | US20100189642 Radionuclides for medical use |
| 07/29/2010 | US20100189641 Novel Strategies for Improved Cancer Vaccines |
| 07/29/2010 | DE10392697B4 Extrakt von Peptid-verknüpften Glucanen und Peptid-verknüpfte Clucane mit nachweisbarer oraler Resorbierbarkeit aus Coriolus Versicolor und deren Reinigungsverfahren und Verwendungen Extract of peptide-linked glucans and peptide-linked Clucane with detectable oral absorbability from Coriolus versicolor and their cleaning methods and uses |
| 07/29/2010 | DE102009006228A1 Liposomal composition, useful to treat e.g. brain metastases, comprises liposomal vesicle, where the vesicles consist of a base lipid, a membrane stabilizer, a helper lipid and a charge carrier, and contain a cytostatic agent and a ligand |
| 07/29/2010 | CA2750581A1 Pta089 protein |
| 07/29/2010 | CA2750106A1 Poly (adp-ribose) polymerase (parp) inhibitors |
| 07/29/2010 | CA2749970A1 Novel heterocyclic compounds as metap-2 inhibitors |
| 07/29/2010 | CA2749097A1 Fruit and vegetable-derived compositions |
| 07/29/2010 | CA2748957A1 Spiroindolinone derivative prodrugs |
| 07/29/2010 | CA2747801A1 N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity |
| 07/28/2010 | EP2210956A2 Method to inhibit cell growth using oligonucleotides |
| 07/28/2010 | EP2210939A1 Anti-bst2 antibody |
| 07/28/2010 | EP2210904A1 Fusion protein comprising tumor necrosis factor related apoptosis inducing ligand and integrin ligand and use thereof |
| 07/28/2010 | EP2210643A2 Combinations comprising epothilones and pharmaceutical uses thereof |
| 07/28/2010 | EP2210616A1 Multifunctional stealth nanoparticles for biomedical use |
| 07/28/2010 | EP2210607A1 N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| 07/28/2010 | EP2210606A2 Methods Of Using And Compositions Comprising Immunomodulatory Compounds For The Treatment And Management Of Myeloproliferative Diseases |
| 07/28/2010 | EP2210092A2 Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof |
| 07/28/2010 | EP2209895A2 Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo |
| 07/28/2010 | EP2209797A2 Modification of intrinsically disordered sequences for preparing vaccines |
| 07/28/2010 | EP2209786A1 Pyrimidine substituted purine derivatives |
| 07/28/2010 | EP2209785A1 2-morpholinylpurines as inhibitors of pi3k |
| 07/28/2010 | EP2209779A1 Heterocyclic urea and thiourea derivatives and methods of use thereof |
| 07/28/2010 | EP2209777A2 Thiazol derivatives for treating cancer |
| 07/28/2010 | EP2209774A1 Pyrimidinedione derivatives |
| 07/28/2010 | EP2209771A1 Cyclobutyl carboxylic acid derivatives |
| 07/28/2010 | EP2209529A2 Isoxazole compound for the treatment of cancer |
| 07/28/2010 | EP2209498A2 Treatment of proliferative disorders using antibodies to psma |
| 07/28/2010 | EP2209495A1 Taz/wwtr1 for diagnosis and treatment of cancer |
| 07/28/2010 | EP2209491A2 Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6) |